Latest News
All Times Eastern
- ‘It’s caused a lot of tension in our marriage’: My wife’s family comes visit, hides food and never cleans up. How do we get rid of them?
- Barron's China’s AI Clout Might Be Overstated. What to Know.
- Barron's This Company Makes Costco and Amazon’s Store Brands. Its Stock Is a Buy.
- Barron's This Carbon-Capture Stock Has Big Plans. Why It’s a Buy.
- Barron's Forget Apple and Nvidia. Why June Belongs to Small-Caps.
- Barron's Market Gains as Wall of Worry Crumbles. What Happens Next.
- Judge in FTX bankruptcy rejects media challenge, says customer names can remain secret
- Barron's Commercial Traders Are Net Long Copper. That’s a Good Sign for the Red Metal.
- Mark Zuckerberg says Meta may be ‘primary beneficiary’ of Apple Vision Pro headset
- Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
to be replaced
PepGen Inc.
PEPGUS
$
-0.08
-0.65%
After Hours
$
12.20
After Hours Volume:
3.66K
| Close | Chg | Chg % |
|---|---|---|
| $12.28 | -4.11 | -25.08% |
Volume: 213.34K
65 Day Avg: 46.35K
11.95
Day Range
16.39
4.32
52 Week Range
20.00
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
PEPG Overview
Key Data
- Open $16.34
- Day Range 11.95 - 16.39
- 52 Week Range 4.32 - 20.00
- Market Cap $389.79M
- Shares Outstanding 23.78M
- Public Float 19.18M
- Beta 1.14
- Rev. per Employee N/A
- P/E Ratio N/A
- EPS -$3.34
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 196.03K 05/31/23
- % of Float Shorted 1.02%
- Average Volume 46.35K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 5
Full Ratings
Recent News
PepGen started at buy with $24 stock price target at Stifel Nicolaus
PepGen started at outperform with $17 stock price target at Wedbush
Activist Investing Covetrus and PepGen Stock See Action From Activist Investors
12 Health Care Stocks Moving In Friday's Intraday Session
on Benzinga.com
SAIC, HealthEquity And 3 Stocks To Watch Heading Into Monday
on Benzinga.com
SVB Securities Remains a Buy on PepGen Inc. (PEPG)
on TipRanks.com
SVB Securities Sticks to Their Buy Rating for PepGen Inc. (PEPG)
on TipRanks.com
PepGen: Q1 Earnings Insights
on Benzinga.com
H.C. Wainwright Keeps Their Buy Rating on PepGen Inc. (PEPG)
on TipRanks.com
Earnings Scheduled For March 23, 2023
on Benzinga.com
PepGen Inc.
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.